Crescent Biopharma (GYRE) Balance Sheet: Assets & Liabilities

Crescent Biopharma (GYRE) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Crescent Biopharma reported total assets of $166.13M and total liabilities of $23.85M. Shareholders' equity was $106.03M, up 7.8% from $98.40M a year earlier. Total debt stood at $939.00K against $52.42M in cash and short-term investments, a net cash position of $51.49M. That puts debt-to-equity at 0.01, compared with 0.02 a year earlier.

Crescent Biopharma Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Crescent Biopharma, Inc. (GYRE) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	37.07	11.81	33.51	25.18	44.35	26.09	30.36	15.37	31.21	14.47
Short-Term Investments	15.36	14.86	0.00	0.00	2.50	0.39	48.99	61.50	88.91	17.97
Cash & Short-Term Investments	52.43	26.67	33.51	25.18	46.85	26.48	79.35	76.87	120.13	32.44
Accounts Receivable	36.95	19.59	15.16	17.14	1.82	10.05	3.31	15.00	0.00	0.02
Inventory	10.17	6.34	4.28	6.12	0.90	5.72	0.00	0.00	0.00	5.31
Other Current Assets	2.83	2.63	2.59	1.22	1.91	2.81	6.84	4.20	3.86	1.33
Total Current Assets	102.37	64.79	57.22	49.65	51.48	44.85	89.51	96.07	123.99	39.11
Non-Current Assets
Property, Plant & Equipment (Net)	24.73	25.70	23.76	18.38	3.71	17.34	2.27	2.23	0.39	0.28
Long-Term Investments	0.00	24.57	23.43	7.39	0.00	-	2.54	0.00	0.00	0.00
Intangible Assets	4.73	1.71	1.70	1.86	3.26	20.76	0.00	0.00	0.00	0.00
Other Non-Current Assets	27.43	34.65	11.91	16.43	-2.79	0.47	0.53	0.26	0.54	0.13
Total Non-Current Assets	63.76	60.62	59.32	35.10	4.19	40.00	5.34	2.49	0.93	0.40
Total Assets	166.13	125.41	116.54	84.75	55.66	84.85	94.85	98.55	124.92	39.51
Current Liabilities
Accounts Payable	0.12	0.11	0.36	0.12	6.42	0.25	5.93	4.28	1.25	0.75
Short-Term Debt	0.64	0.71	0.21	0.49	1.98	-	0.66	0.48	0.00	5.09
Accrued Liabilities	14.35	10.62	11.94	9.26	-	5.54	-	-	-	-
Deferred Revenue	0.11	0.06	0.04	0.15	0.23	0.23	1.98	15.00	0.00	0.21
Other Current Liabilities	14.48	8.02	7.51	2.22	5.54	-	9.22	9.14	3.55	2.70
Total Current Liabilities	18.29	19.52	20.05	12.24	14.17	10.30	17.80	28.90	4.80	8.74
Non-Current Liabilities
Long-Term Debt	0.30	0.89	0.20	0.12	0.41	0.74	0.98	1.32	0.00	0.00
Other Non-Current Liabilities	4.41	6.60	17.82	0.17	0.00	-	0.00	0.00	0.17	0.00
Total Non-Current Liabilities	5.56	7.49	18.02	0.29	0.41	1.63	0.98	1.32	0.17	0.00
Total Liabilities	23.85	27.00	38.07	12.54	14.57	11.93	18.78	30.22	4.98	8.74
Stockholders' Equity
Common Stock	0.00	0.09	0.08	0.06	0.03	9.62	0.02	0.01	0.01	0.01
Retained Earnings	-68.43	-70.36	-82.44	10.06	-402.69	23.08	-314.76	-258.52	-203.34	-173.49
Accumulated Other Comprehensive Income	2.32	-2.60	-1.64	-0.39	0.00	40.23	0.01	0.03	0.00	0.00
Additional Paid-in Capital	172.14	136.19	68.18	32.80	443.75	-	390.80	326.81	323.28	204.26
Minority Interest	36.25	35.08	29.78	29.70	0.00	-	0.00	0.00	0.00	0.00
Shares Outstanding	91.31	86.31	76.60	76.58	-	76.58	-	-	-	-
Total Stockholders' Equity	106.03	98.40	78.47	72.22	41.09	72.92	76.07	68.34	119.95	30.77
Total Liabilities & Equity	166.13	125.41	116.54	84.75	55.66	84.85	94.85	98.55	124.92	39.51

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Crescent Biopharma Balance Sheet

How much debt does Crescent Biopharma have?

Crescent Biopharma had total debt of $939.00K as of Dec 31, 2025, against $52.42M in cash and short-term investments. Its debt-to-equity ratio was 0.01. Total debt was $1.60M a year earlier.

What are Crescent Biopharma's total assets?

Crescent Biopharma reported total assets of $166.13M as of Dec 31, 2025, up 32.5% from $125.41M a year earlier. Total liabilities were $23.85M.

What is Crescent Biopharma's shareholders' equity?

Crescent Biopharma's shareholders' equity was $106.03M as of Dec 31, 2025, or about $1.16 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition